Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study
出版年份 2022 全文链接
标题
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 3, Pages e004157
出版商
BMJ
发表日期
2022-03-10
DOI
10.1136/jitc-2021-004157
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action
- (2021) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
- (2021) Barliz Waissengrin et al. LANCET ONCOLOGY
- Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
- (2021) Lee M. Greenberger et al. CANCER CELL
- Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution
- (2021) Elizabeth A. Griffiths et al. CANCER CELL
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- (2021) Huiyan Luo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
- (2021) Nader Yatim et al. Science Advances
- Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
- (2021) Jing Ni et al. Frontiers in Oncology
- Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
- (2021) C. Corti et al. ANNALS OF ONCOLOGY
- Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis
- (2021) Andrea Becerril-Gaitan et al. EUROPEAN JOURNAL OF CANCER
- Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
- (2021) Vivek Naranbhai et al. JOURNAL OF CLINICAL ONCOLOGY
- A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
- (2021) A. Lasagna et al. ESMO Open
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
- (2018) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
- (2018) Arabella Young et al. Cancer Immunology Research
- High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy
- (2016) Suresh Gopi Kalathil et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started